Christine Lochner1, Samuel R Chamberlain2, Martin Kidd3, Naomi A Fineberg2,4, Dan J Stein5. 1. US/UCT MRC Unit on Anxiety & Stress Disorders, Department of Psychiatry, University of Stellenbosch, PO Box 241, Cape Town, 8000, South Africa. cl2@sun.ac.za. 2. Department of Psychiatry, University of Cambridge School of Clinical Medicine and Cambridge and Peterborough NHS Foundation Trust (CPFT), Cambridge, UK. 3. Centre for Statistical Consultation, Department of Statistics and Actuarial Sciences, University of Stellenbosch, Stellenbosch, South Africa. 4. Hertfordshire Partnership University NHS Foundation Trust and University Of Hertfordshire, Hatfield, UK. 5. US/UCT MRC Unit on Anxiety & Stress Disorders, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.
Abstract
RATIONALE: Obsessive-compulsive disorder (OCD) implicates dysfunction of orbitofrontal and insula-related circuitry and of the serotonin system. There is an on-going search in psychiatry for intermediate biological markers, termed 'endophenotypes', that exist not only in patients with a given disorder but also in their clinically unaffected first-degree relatives. OBJECTIVE: Pharmacological challenge is recognized as a means of eliciting an endophenotype, but this strategy has yet to be used in OCD. METHODS:Twenty-three OCD patients without comorbidities (12 [52.2 %] female), 13 clinically asymptomatic first-degree relatives of OCD patients (11 [84.6 %] female) and 27 healthy controls (16 [59.3 %] female) receivedsingle-dose escitalopram (20 mg) and placebo in a randomized double-blind crossover design. Effects of treatment on decision-making were quantified using the Cambridge Gamble Task (CGT) in conjunction with a mixed model analysis of covariance (ANCOVA). RESULTS: There was a significant interaction between serotonergic challenge and group for risk adjustment on the CGT (F = 4.1406; p = 0.02). Only controls showed a significant placebo-drug change in risk adjustment (p = 0.02; versus p > 0.10). Numerically, escitalopram was associated with increase in risk adjustment in controls and reductions in the other groups. Change in risk adjustment was similar in OCD patients and relatives (p = 0.806) and differed significantly from controls (p = 0.007; p = 0.041, respectively). CONCLUSIONS: Individuals with OCD, and first-degree relatives, showed an altered cognitive response to serotonin challenge. This is the first demonstration of a candidate pharmacological challenge endophenotype for the disorder. Future work should confirm these findings in a larger sample size and ideally extend them to other cognitive paradigms, utilizing functional neuroimaging.
RCT Entities:
RATIONALE: Obsessive-compulsive disorder (OCD) implicates dysfunction of orbitofrontal and insula-related circuitry and of the serotonin system. There is an on-going search in psychiatry for intermediate biological markers, termed 'endophenotypes', that exist not only in patients with a given disorder but also in their clinically unaffected first-degree relatives. OBJECTIVE: Pharmacological challenge is recognized as a means of eliciting an endophenotype, but this strategy has yet to be used in OCD. METHODS: Twenty-three OCDpatients without comorbidities (12 [52.2 %] female), 13 clinically asymptomatic first-degree relatives of OCDpatients (11 [84.6 %] female) and 27 healthy controls (16 [59.3 %] female) received single-dose escitalopram (20 mg) and placebo in a randomized double-blind crossover design. Effects of treatment on decision-making were quantified using the Cambridge Gamble Task (CGT) in conjunction with a mixed model analysis of covariance (ANCOVA). RESULTS: There was a significant interaction between serotonergic challenge and group for risk adjustment on the CGT (F = 4.1406; p = 0.02). Only controls showed a significant placebo-drug change in risk adjustment (p = 0.02; versus p > 0.10). Numerically, escitalopram was associated with increase in risk adjustment in controls and reductions in the other groups. Change in risk adjustment was similar in OCDpatients and relatives (p = 0.806) and differed significantly from controls (p = 0.007; p = 0.041, respectively). CONCLUSIONS: Individuals with OCD, and first-degree relatives, showed an altered cognitive response to serotonin challenge. This is the first demonstration of a candidate pharmacological challenge endophenotype for the disorder. Future work should confirm these findings in a larger sample size and ideally extend them to other cognitive paradigms, utilizing functional neuroimaging.
Authors: F C Murphy; J S Rubinsztein; A Michael; R D Rogers; T W Robbins; E S Paykel; B J Sahakian Journal: Psychol Med Date: 2001-05 Impact factor: 7.723
Authors: S Erzegovesi; M C Cavallini; P Cavedini; G Diaferia; M Locatelli; L Bellodi Journal: J Clin Psychopharmacol Date: 2001-10 Impact factor: 3.153
Authors: Lara Menzies; Samuel R Chamberlain; Angela R Laird; Sarah M Thelen; Barbara J Sahakian; Ed T Bullmore Journal: Neurosci Biobehav Rev Date: 2007-10-17 Impact factor: 8.989
Authors: Samuel R Chamberlain; Lara Menzies; Adam Hampshire; John Suckling; Naomi A Fineberg; Natalia del Campo; Mike Aitken; Kevin Craig; Adrian M Owen; Edward T Bullmore; Trevor W Robbins; Barbara J Sahakian Journal: Science Date: 2008-07-18 Impact factor: 47.728
Authors: Christine Lochner; Samuel R Chamberlain; Martin Kidd; Lian Taljaard; Naomi A Fineberg; Trevor W Robbins; Dan J Stein Journal: Psychopharmacology (Berl) Date: 2020-07-08 Impact factor: 4.530